O075 Update in the management of Pierre Robin Sequence

Abstract Background Pierre Robin sequence (PRS) is a congenital triad of micrognathia, glossoptosis and airway obstruction. Current treatment approaches in Australia include nasopharyngeal airway, continuous positive airway pressure, and surgery including mandibular distraction osteogenesis. The Tübingen Palatal Plate (TPP) offers an orthodontic method for jaw distraction that has hitherto not been available in Australia. Since October 2023, we have assembled the team required to implement this treatment. This study evaluates the outcomes of patients managed with TPP at our centre, to date. Methods Retrospective analysis comparing treatment outcomes for patients diagnosed with PRS managed at a tertiary paediatric centre from October 2023 to October 2024. Progress to date Of ten patients with PRS treated at our centre since October 2023, seven (70%) were treated with TPP. Eight (80%) patients underwent polysomnography (PSG) prior to intervention. The mean apnoea hypopnea index (AHI) was 49.6 events/hr (±24.1; 16.4-88.5) and obstructive apnoea hypopnea index (OAHI) was 43.2 events/hr (±24.4; 15.5-88.5). A repeat PSG within 3 weeks post intervention demonstrated improvement in AHI by 24 events/hr (±24.9; -3.8-66; p=0.06) and OAHI by 18 events/hr (±9.2; 4.9-31.4; p=0.09). At the time of submission, 2 patients have completed TPP treatment with final PSG AHI/OAHI values of 4.5/3.4 and 9.4/3 respectively. This demonstrates mean reduction in AHI scores of 28.8 events/hr (±21.6; 11.9-45.7; p=0.33) and OAHI 22.7 events/hr (±15.5; 12.5-32.9; p=0.27). Intended outcome and impact We have successfully implemented TPP therapy for PRS in Australia, confirming its effectiveness as an orthodontic method of jaw distraction.